Advertisement

Letter to Editor Re: “Combined Quantification of 18F-FDG and 68Ga-DOTATATE PET/CT for Prognosis in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms” (https://doi.org/10.1016/j.acra.2021.10.004)

Published:February 23, 2022DOI:https://doi.org/10.1016/j.acra.2022.01.012
      To: N. Reed Dunnick, DM
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Academic Radiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lee H
        • Nakamoto R
        • Moore SE
        • et al.
        Combined quantification of 18F-FDG and 68Ga-DOTATATE PET/CT for prognosis in high-grade gastroenteropancreatic neuroendocrine neoplasms.
        Acad Radiol. 2021; S1076633221004621
        • Zhang J
        • Kulkarni HR
        • Singh A
        • et al.
        Peptide receptor radionuclide therapy in grade 3 neuroendocrine neoplasms: safety and survival analysis in 69 patients.
        J Nucl Med. 2019; 60: 377-385
        • Thang SP
        • Lung MS
        • Kong G
        • et al.
        Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis.
        Eur J Nucl Med Mol Imaging. 2018; 45: 262-277
        • Chan DL
        • Pavlakis N
        • Schembri GP
        • et al.
        Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance.
        Theranostics. 2017; 7: 1149-1158